1357476-64-2
C9H9F3O2
206.16
Breast cancer
Alpelisib
4/29/2033 (Alpelisib)
PI3Kα
Availability: | |
---|---|
DESCRIPTION
As the first-in-class oral PI3K inhibitor, Alpelisib offers targeted therapy for advanced or metastatic hormone receptor-positive, HER2-negative breast cancer with a PIK4CA mutation. This groundbreaking drug provides a personalized approach, enhancing treatment outcomes while minimizing toxicity. By incorporating Alpelisib into your pharmaceutical portfolio, you can champion precision medicine and make a significant impact on patients' lives. Embrace Alpelisib and join the fight against breast cancer with innovation and compassion.
content is empty!